Compare CHCT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHCT | TRDA |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | 183 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.1M | 481.6M |
| IPO Year | 2015 | 2021 |
| Metric | CHCT | TRDA |
|---|---|---|
| Price | $16.63 | $12.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $18.33 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 356.3K | 191.6K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 11.46% | N/A |
| EPS Growth | ★ 134.78 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $121,195,000.00 | $25,421,000.00 |
| Revenue This Year | $9.06 | $51.37 |
| Revenue Next Year | $8.61 | $46.98 |
| P/E Ratio | $208.38 | ★ N/A |
| Revenue Growth | ★ 4.67 | N/A |
| 52 Week Low | $13.23 | $4.93 |
| 52 Week High | $18.90 | $12.93 |
| Indicator | CHCT | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 59.95 |
| Support Level | $16.18 | $9.59 |
| Resistance Level | $17.34 | N/A |
| Average True Range (ATR) | 0.52 | 0.86 |
| MACD | -0.08 | 0.09 |
| Stochastic Oscillator | 27.37 | 84.15 |
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems, or other healthcare service providers in non-urban markets. The company derives the majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.